Risk factors for infectious complications following transrectal ultrasound-guided prostate biopsy

Yu-Peng Wu, Xiao-Dong Li, Zhi-Bin Ke, Shao-Hao Chen, Ping-Zhou Chen, Yong Wei, Jin-Bei Huang, Xiong-Lin Sun, Xue-Yi Xue, Qing-Shui Zheng, Ning Xu, Yu-Peng Wu, Xiao-Dong Li, Zhi-Bin Ke, Shao-Hao Chen, Ping-Zhou Chen, Yong Wei, Jin-Bei Huang, Xiong-Lin Sun, Xue-Yi Xue, Qing-Shui Zheng, Ning Xu

Abstract

Objective: To explore risk factors of infectious complications following transrectal ultrasound-guided prostate biopsy (TRUSPB).

Methods: We retrospectively analyzed 1,203 patients with suspected prostate cancer who underwent TRUSPB at our center between December 2012 and December 2016. Demographics, clinical characteristics, and data regarding complications were collected, and then univariate and multivariate logistic regression analyses were used to identify independent risk factors for infectious complications after prostate biopsy.

Results: Multivariate logistic analysis demonstrated that body mass index (BMI) (OR=2.339, 95% CI 2.029-2.697, P<0.001), history of diabetes (OR=2.203, 95% CI 1.090-4.455, P=0.028), and preoperative catheterization (OR=2.303, 95% CI 1.119-4.737, P=0.023) were risk factors for infection after prostate biopsy. The area under the receiver operating characteristics curve for infectious complications was 0.930 (95% CI 0.907-0.953, P<0.001). BMI=28.196 kg/m2 was the best cut-off threshold for predicting infection after TRUSPB.

Conclusion: BMI >28.196 kg/m2, history of diabetes, and preoperative catheterization are independent risk factors for infection after prostate biopsy.

Keywords: body mass index; diabetes mellitus; infectious complications; preoperative catheterization; transrectal ultrasound-guided prostate biopsy.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
    1. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–1092.
    1. Lu DD, Raman JD. Strategies for prevention of ultrasound-guided prostate biopsy infections. Infect Drug Resist. 2016;9:161–169.
    1. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64(6):876–892.
    1. Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ. 2012;344:d7894.
    1. Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013;189(1 Suppl):S12–S18.
    1. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186(5):1830–1834.
    1. Carignan A, Roussy JF, Lapointe V, Valiquette L, Sabbagh R, Pépin J. Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? Eur Urol. 2012;62(3):453–459.
    1. Chiang BJ, Pu YS, Chung SD, et al. Quinolone prophylaxis in transrectal ultrasound guided prostate biopsy: an eight-year single center experience. ScientificWorldJournal. 2013;2013:452107.
    1. Zhang XH, Jia Y, Guo WH, et al. Clinical comparison of the efficacy of three different bowel preparation methods on the infectious complications following transrectal ultrasonography-guided prostate biopsy in nursing practice. J Clin Nurs. 2018;27(13-14):2583–2589.
    1. Wu X, Yu C, Li T, et al. Obesity was an independent risk factor for febrile infection after prostate biopsy: A 10-year single center study in South China. Medicine. 2018;97(1):e9549.
    1. Qiao LD, Chen S, Wang XF, et al. A multi-center, controlled, randomized, open-label clinical study of levofloxacin for preventing infection during the perioperative period of ultrasound-guided transrectal prostate biopsy. Eur J Clin Microbiol Infect Dis. 2016;35(11):1877–1881.
    1. Wang J, Wan B, Li C, et al. Diagnostic Yield and Complications Using a 20 Gauge Prostate Biopsy Needle versus a Standard 18 Gauge Needle: A Randomized Controlled Study. Urol J. 2015;12(5):2329–2333.
    1. Eruz ED, Yalci A, Ozden E, et al. Risk factors for infection development after transrectal prostate biopsy and the role of resistant bacteria in colonic flora. J Infect Dev Ctries. 2017;11(2):188–191.
    1. Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL. Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. Clin Infect Dis. 2013;57(2):267–274.
    1. Shakir NA, Siddiqui MM, George AK, et al. Should Hypoechoic Lesions on Transrectal Ultrasound Be Sampled During Magnetic Resonance Imaging-targeted Prostate Biopsy? Urology. 2017;105:113–117.
    1. Na R, Ye D, Qi J, et al. Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China. Prostate. 2017;77(11):1221–1229.
    1. Whitson JM, Porten SP, Hilton JF, et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011;185(5):1656–1660.
    1. Choi JW, Kim TH, Chang IH, et al. Febrile urinary tract infection after prostate biopsy and quinolone resistance. Korean J Urol. 2014;55(10):660–664.
    1. Hashimoto T, Namiki K, Tanaka A, Shimodaira K, Gondo T, Tachibana M. Emphysematous cystitis following a transrectal needle guided biopsy of the prostate. BMC Infect Dis. 2012;12(1):322.
    1. Xu N, Xue XY, Li XD, Wei Y, Lin N. Meperidine relieves pain during transrectal ultrasound-guided prostate biopsy. Saudi Med J. 2014;35(5):454–459.
    1. Lai CY, Tian L, Schisterman EF. Exact confidence interval estimation for the Youden index and its corresponding optimal cut-point. Comput Stat Data Anal. 2012;56(5):1103–1114.
    1. Caminha TC, Ferreira HS, Costa NS, et al. Waist-to-height ratio is the best anthropometric predictor of hypertension: A population-based study with women from a state of northeast of Brazil. Medicine. 2017;96(2):e5874.
    1. Hasegawa T, Shimomura T, Yamada H, et al. Fatal septic shock caused by transrectal needle biopsy of the prostate; a case report. Kansenshogaku Zasshi. 2002;76(10):893–897.
    1. Batura D, Gopal Rao G. The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J Antimicrob Chemother. 2013;68(2):247–249.
    1. Simsir A, Kismali E, Mammadov R, Gunaydin G, Cal C. Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int. 2010;84(4):395–399.
    1. Wagenlehner FM, van Oostrum E, Tenke P, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol. 2013;63(3):521–527.
    1. Pinkhasov GI, Lin YK, Palmerola R, et al. Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases. BJU Int. 2012;110(3):369–374.
    1. Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012;61(6):1110–1114.
    1. Semins MJ, Shore AD, Makary MA, Weiner J, Matlaga BR. The impact of obesity on urinary tract infection risk. Urology. 2012;79(2):266–269.
    1. Dotters-Katz SK, Feldman C, Puechl A, Grotegut CA, Heine RP. Risk factors for post-operative wound infection in the setting of chorioamnionitis and cesarean delivery. J Matern Fetal Neonatal Med. 2016;29(10):1541–1545.
    1. Sebastian A, Huddleston P, Kakar S, Habermann E, Wagie A, Nassr A. Risk factors for surgical site infection after posterior cervical spine surgery: an analysis of 5,441 patients from the ACS NSQIP 2005–2012. Spine J. 2016;16(4):504–509.
    1. Khan MN, Russo J, Spivack J, et al. Association of Body Mass Index With Infectious Complications in Free Tissue Transfer for Head and Neck Reconstructive Surgery. JAMA Otolaryngol Head Neck Surg. 2017;143(6):574–579.
    1. Tsu JH, Ma WK, Chan WK, et al. Prevalence and predictive factors of harboring fluoroquinolone-resistant and extended-spectrum β-lactamase-producing rectal flora in Hong Kong Chinese men undergoing transrectal ultrasound-guided prostate biopsy. Urology. 2015;85(1):15–22.
    1. Aus G, Ahlgren G, Bergdahl S, Hugosson J. Infection after transrectal core biopsies of the prostate--risk factors and antibiotic prophylaxis. Br J Urol. 1996;77(6):851–855.
    1. de Jesus CM, Corrêa LA, Padovani CR. Complications and risk factors in transrectal ultrasound-guided prostate biopsies. Sao Paulo Med J. 2006;124(4):198–202.
    1. Steensels D, Slabbaert K, de Wever L, Vermeersch P, van Poppel H, Verhaegen J. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect. 2012;18(6):575–581.
    1. Taylor AK, Murphy AB. Preprostate Biopsy Rectal Culture and Post-biopsy Sepsis. Urol Clin North Am. 2015;42(4):449–458.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever